B-Cell Malignant Neoplasm — Trials

B-Cell Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

7,464 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,083
Recruiting: 1,078
Ph III recruiting: 121
Growth YoY: +5.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,165)

clinicaltrialsPublishedShowing 1–50 of 3,534 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03223610	Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	recruiting	Phase 1 / Phase 2	155	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT03412877	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	recruiting	Phase 2	285	National Cancer Institute (NCI)NIH	1	Sep 28, 2026